Founder, Flame Biosciences
Senior Scientific Advisor
Patrick (Pat) Scannon is one of the founders of XOMA Corporation, a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for unmet medical needs, including the BioSecurity market. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon is also an expert on IL-1ß antibodies. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to numerous pharma and biotech companies. From 1979 until 1981, Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco.
A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an M.D. from the Medical College of Georgia.